Leqvio (Inclisiran) and Tadalafil Interaction

Why These Two Drugs Get Prescribed Together

Patients receiving Leqvio (inclisiran) for LDL-cholesterol reduction often have atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). Many of these same patients use tadalafil for erectile dysfunction or benign prostatic hyperplasia. The overlap is common. Men with ASCVD carry a 2- to 3-fold higher prevalence of erectile dysfunction compared to age-matched controls, according to data from the Massachusetts Male Aging Study 1.

Inclisiran received FDA approval in December 2021 for adults with HeFH or clinical ASCVD who need additional LDL lowering 2. Tadalafil (Cialis) has been available since 2003 for erectile dysfunction and since 2011 for BPH at the 5 mg daily dose 3. Because cardiovascular disease and erectile dysfunction share endothelial dysfunction as a root cause 4, co-prescription is a routine clinical scenario.

Inclisiran's Unique Mechanism Eliminates Most Drug-Drug Interaction Concerns

Inclisiran is a synthetic small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc). This conjugate directs the molecule specifically to hepatocyte asialoglycoprotein receptors. Once internalized, inclisiran binds PCSK9 messenger RNA in the RNA-induced silencing complex (RISC), triggering catalytic degradation of PCSK9 mRNA and reducing circulating PCSK9 protein 5.

This mechanism matters for drug interactions. Unlike statins, ezetimibe, or PCSK9 monoclonal antibodies, inclisiran does not circulate systemically at pharmacologically relevant concentrations after hepatocyte uptake. The FDA label states inclisiran is "not a substrate, inhibitor, or inducer of CYP450 enzymes or common drug transporters (P-gp, OATP, OAT, OCT, BCRP, MRP2, MATE)" 2. Endogenous ribonucleases degrade inclisiran. No hepatic enzymatic processing occurs through the pathways that drive conventional drug-drug interactions.

Tadalafil, by contrast, is metabolized primarily by CYP3A4 3. Drugs that inhibit or induce CYP3A4 (ketoconazole, rifampin, ritonavir) alter tadalafil exposure significantly. Inclisiran does neither.

Pharmacokinetic Analysis: No Interaction Pathway Exists

A pharmacokinetic interaction requires that one drug alter the absorption, distribution, metabolism, or excretion of the other. Between inclisiran and tadalafil, no such pathway exists.

Absorption. Inclisiran is administered as a subcutaneous injection by a healthcare professional every 6 months (after initial and 3-month doses). Tadalafil is taken orally. Their absorption routes do not overlap. Inclisiran reaches peak plasma concentration at approximately 4 hours post-injection before rapid hepatic uptake clears it from circulation 6.

Distribution. Inclisiran shows 87% plasma protein binding, predominantly to albumin 2. Tadalafil is 94% protein-bound 3. Protein binding displacement interactions are clinically meaningful only when both drugs are highly bound AND have a narrow therapeutic index. Neither drug meets the narrow therapeutic index criterion, and inclisiran is cleared from plasma within 24-48 hours of injection.

Metabolism. This is the decisive factor. Inclisiran undergoes nuclease-mediated degradation. It does not interact with CYP3A4, CYP2C9, CYP2D6, or any other cytochrome P450 isoenzyme 2. Tadalafil's CYP3A4-dependent metabolism proceeds unaffected.

Excretion. Approximately 16% of an inclisiran dose is recovered in urine as intact drug. Renal excretion of tadalafil metabolites (predominantly catechol and methylcatechol glucuronides) uses different transporter systems 3. No competitive inhibition at the renal tubule is expected.

Pharmacodynamic Considerations: Blood Pressure Overlap

The one area warranting clinical attention is additive blood pressure reduction. This is a pharmacodynamic interaction, not pharmacokinetic.

Tadalafil produces mild systemic vasodilation through nitric oxide/cGMP pathway enhancement. In healthy volunteers, tadalafil 20 mg lowered supine systolic blood pressure by a mean of 1.6 mmHg and diastolic by 0.8 mmHg 3. The effect is more pronounced in patients already taking antihypertensives, where additive drops of 3-4 mmHg systolic have been documented 7.

Inclisiran's blood pressure effect is smaller but present. In the ORION-11 trial (N=1,617), inclisiran-treated patients showed a modest systolic blood pressure reduction of approximately 1-2 mmHg versus placebo, likely secondary to improved endothelial function from aggressive LDL lowering 8. The ORION-10 trial (N=1,561) confirmed similar hemodynamic stability with no excess hypotensive events in the inclisiran arm 8.

For patients on both drugs who also take antihypertensives (a common three-drug overlap in the ASCVD population), the combined blood pressure effect could reach 4-6 mmHg systolic. This is unlikely to cause symptomatic hypotension in most patients, but it warrants monitoring in those with baseline systolic blood pressure below 110 mmHg or those taking alpha-blockers concurrently. The American Urological Association notes that PDE5 inhibitors should be initiated at the lowest dose in patients on alpha-blockers due to hypotension risk 9.

What the Clinical Trials Show

The ORION trial program evaluated inclisiran in over 3,600 patients across multiple phase III studies. Concomitant medication data from ORION-9 (HeFH, N=482), ORION-10 (ASCVD, N=1,561), and ORION-11 (ASCVD/HeFH, N=1,617) show that patients were taking a wide range of cardiovascular medications 8 10.

Specific PDE5 inhibitor use was not reported as a subgroup, but patients on antihypertensives, anticoagulants, antiplatelets, and other vasoactive drugs were included without dose restrictions on inclisiran. No signal for hemodynamic instability emerged. The pooled safety analysis showed injection site reactions (8.2% vs. 1.8% placebo) as the primary adverse event difference 11. Hypotension was not identified as an adverse event of special interest in any ORION trial.

The three-year open-label extension data from ORION-3 (N=382) demonstrated sustained LDL lowering (approximately 47.5% reduction) with a safety profile consistent with the key trials, and no new drug-interaction signals appeared over extended follow-up 12.

Monitoring Recommendations for Patients on Both Drugs

Although no formal interaction exists, standard clinical practice calls for pragmatic monitoring when combining a cholesterol-lowering injectable with a vasoactive oral medication.

At each inclisiran injection visit (every 6 months after the loading period): measure seated blood pressure before and 15 minutes after injection. Document any concurrent PDE5 inhibitor use in the medication reconciliation. Check a lipid panel to confirm LDL response.

For tadalafil dosing: no dose adjustment is needed based on inclisiran co-administration. The standard erectile dysfunction dose range (5-20 mg as needed or 2.5-5 mg daily) applies 3. For BPH, the 5 mg daily dose remains appropriate.

For patients on triple therapy (inclisiran + tadalafil + antihypertensive): the 2017 ACC/AHA hypertension guideline recommends a blood pressure target of <130/80 mmHg for patients with established ASCVD 13. If blood pressure falls below 100/60 mmHg with symptoms (dizziness, lightheadedness), the antihypertensive dose should be adjusted before discontinuing either inclisiran or tadalafil.

Liver function: inclisiran's hepatocyte-targeted mechanism raises theoretical hepatotoxicity questions, but ALT/AST elevations occurred at similar rates in inclisiran and placebo groups across ORION trials 2. Tadalafil undergoes hepatic metabolism but does not carry a hepatotoxicity warning. Routine liver function testing beyond standard cardiovascular care is not required for the combination.

Tadalafil Interactions That Actually Matter

While inclisiran poses no interaction risk with tadalafil, several other drug classes do. Patients and clinicians should focus attention on these genuine concerns.

Nitrates. The combination of tadalafil with any organic nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) is absolutely contraindicated. Nitrates increase cGMP production through guanylate cyclase stimulation; tadalafil prevents cGMP breakdown via PDE5 inhibition. The result is precipitous, potentially fatal hypotension 3. The 2012 Endocrine Society clinical practice guideline on testosterone therapy reinforces that PDE5 inhibitors must never be combined with nitrates 14.

Alpha-blockers. Tamsulosin, doxazosin, and other alpha-1 antagonists combined with tadalafil can produce orthostatic hypotension. The FDA label recommends that patients be stable on alpha-blocker therapy before starting tadalafil, and that tadalafil be initiated at 5 mg in this population 3.

Strong CYP3A4 inhibitors. Ketoconazole 400 mg daily increased tadalafil AUC by 312% in a pharmacokinetic study 3. Ritonavir produces a similar effect. The maximum recommended tadalafil dose with strong CYP3A4 inhibitors is 10 mg every 72 hours.

Riociguat. This soluble guanylate cyclase stimulator, used in pulmonary hypertension, is contraindicated with all PDE5 inhibitors due to synergistic hypotension through the same cGMP pathway as nitrates 15.

Inclisiran's Known Interaction Profile

The inclisiran FDA label lists no contraindicated drug combinations and no required dose adjustments for concomitant medications 2. This is consistent with its siRNA mechanism.

In the ORION trials, patients received inclisiran alongside statins (atorvastatin, rosuvastatin), ezetimibe, antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, beta-blockers, diuretics), antiplatelets (aspirin, clopidogrel), and anticoagulants (warfarin, DOACs) without evidence of bidirectional pharmacokinetic effects 8. The European Medicines Agency's assessment report confirmed no clinically relevant interactions in dedicated in vitro and clinical pharmacology studies 16.

A 2023 review in the European Heart Journal summarized the interaction profile of all PCSK9-targeted therapies (evolocumab, alirocumab, inclisiran) and concluded that the siRNA class carries the lowest drug-interaction potential of any lipid-lowering drug class currently available 17.

Patient Counseling Points

Patients should hear three things from their prescriber. First, inclisiran and tadalafil do not interact through any known mechanism; no timing adjustments or dose changes are required. Second, tadalafil's real interaction dangers are with nitrates and alpha-blockers, not with cholesterol medications. Third, any new dizziness or lightheadedness after starting either drug should be reported, as it may reflect additive blood pressure lowering rather than a direct drug interaction, and it is correctable with antihypertensive dose adjustment.

Patients taking tadalafil 5 mg daily for BPH should continue their dose unchanged on the day of an inclisiran injection. The injection is administered by a healthcare professional in-office, providing an opportunity for blood pressure monitoring during the visit.